Tremfya and liver fibrosis progression with psoriasis

[Fred]

This study looked at liver fibrosis in psoriasis patients treated with Tremfya (guselkumab)

Quote:

---

Psoriasis is associated with comorbidities like metabolic syndrome and nonalcoholic fatty liver disease, increasing the risk of liver fibrosis.

This study evaluated the long-term effects of guselkumab on liver fibrosis in 154 psoriasis patients using the Fibrosis-4 (FIB-4) index, a noninvasive marker of fibrosis, over 3 years.

Patients were stratified by baseline FIB-4 (≥ 1.3 or < 1.3) and age (35–65 years). Mean FIB-4 values remained stable across all subgroups, with no significant changes observed. High-risk patients (FIB-4 ≥ 1.3) showed minor, nonsignificant fluctuations, while low-risk patients (FIB-4 < 1.3) exhibited a mild, age-related upward trend.

Disease duration emerged as a key factor influencing FIB-4, highlighting the importance of early treatment. These findings suggest guselkumab does not contribute to liver fibrosis progression in psoriasis patients.

Further research with advanced methods like imaging or biopsy is needed to confirm the long-term hepatic safety of IL-23 inhibitors like guselkumab.

Source: onlinelibrary.wiley.com

*Funding: The authors received no specific funding for this work

[post=115641]

[Kat]

I've wondered about treatments and liver disease. Good to know.

[mataribot]

I wonder how real life instances of liver disease was found in patients using biologicals - I wonder how many of them were taking a certain other drug.

[Kat]

I wonder how real life instances of liver disease was found in patients using biologicals - I wonder how many of them were taking a certain other drug.

True, even over the counter meds can be harsh on the liver if overused.